Curcumin: Therapeutical potential in ophthalmology

Planta Medica

Volumn 80, Issue 4, 2014, Pages 249-254

  Pescosolido, Nicola ^a   Giannotti, Rossella ^a   Plateroti, Andrea Maria ^a   Pascarella, Antonia ^b   Nebbioso, Marcella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

anti inflammatory drug; antioxidant drug; antitumor drug; Curcuma longa; Curcumin; ocular diseases; Zingiberaceae

Indexed keywords

CURCUMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

DRUG BIOAVAILABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; NONHUMAN; OPHTHALMOLOGY; REVIEW;

CURCUMA LONGA; ZINGIBERACEAE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CURCUMA; CURCUMIN; EYE DISEASES; HUMANS; OPHTHALMOLOGY; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84896082727     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0033-1351074     Document Type: Review

References (64)

1. Shishodia S. Molecular mechanisms of curcumin action: gene expression. Biofactors: 2013; 39 37 55
2. Talero E., Ávila-Roman J., Motilva V. Chemoprevention with phytonutrients and microalgae products in chronic inflammation and colon cancer. Curr Pharm Des: 2012; 18 3939 3965
3. Ammon H. P., Wahl M. A. Pharmacology of Curcuma longa. Planta Med: 1991; 57 1 7
4. Tamvakopoulos C., Dimas K., Sofianos Z. D., Hatziantoniou S., Han Z., Liu Z. L., Wyche J. H., Pantazis P. Metabolism and anticancer activity of curcumin analogue, dimethoxycurcumin. Clin Cancer Res: 2007; 13 1269 1277 (Pubitemid 46424068)
5. Taylor R. A., Leonard M. C. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev: 2011; 16 152 156
6. Carmona-Ramírez I., Santamaría A., Tobón-Velasco J. C., Orozco-Ibarra M., González-Herrera I. G., Pedraza-Chaverrí J., Maldonado P. D. Curcumin restores Nrf2 levels and prevents quinolinic acid-induced neurotoxicity. J Nutr Biochem: 2013; 24 14 24
7. Aggarwal S., Ichikawa H., Takada Y., Sandur S. K., Shishodia S., Aggarwal B. B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of I κ B α Kinase and akt activation. Mol Pharmacol: 2006; 69 195 206 (Pubitemid 43048906)
8. PrudÊhomme G. J. Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des: 2012; 18 2838 2849
9. Michalik L., Auwerx J., Berger J. P., Chatterjee V. K., Glass C. K., Gonzalez F. J., Grimaldi P. A., Kadowaki T., Lazar M. A., OÊRahilly S., Palmer C. N., Plutzky J., Reddy J. K., Spiegelman B. M., Staels B., Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev: 2006; 58 726 741 (Pubitemid 44833742)
10. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P. S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med: 1998; 64 353 356 (Pubitemid 28234275)
11. Yue G. GL, Cheng S. W., Yu H., Xu Z. S., Lee J. K., Hon P. M., Lee M. Y., Kennelly E. J., Deng G., Yeung S. K., Cassileth B. R., Fung K. P., Leung P. C., Lau C. B. The role of turmerones on curcumin transportation and P-glycoprotein activities in intestinal Caco-2 cells. J Med Food: 2012; 15 242 252
12. Antony B., Merina B., Iyer V. S., Judy N., Lennertz K., Joyal S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax™), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci: 2008; 70 445 449
13. Rachmawati H., Shaal L. A., Müller R. H., Keck C. M. Development of curcumin nanocrystal: physical aspects. J Pharm Sci: 2013; 102 204 214
14. Li L., Ahmed B., Mehta K., Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther: 2007; 6 1276 1282 (Pubitemid 46711990)
15. Kumar V., Lewis S. A., Mutalik S., Shenoy D. B. Venkatesh Udupa N. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol: 2002; 46 209 217 (Pubitemid 34415120)
16. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., Maitra A. Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy. J Nanobiotechnol: 2007; 5 3
17. Gong C., Deng S., Wu Q., Xiang M., Wei X., Li L., Gao X., Wang B., Sun L., Chen Y., Li Y., Liu L., Qian Z., Wei Y. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials: 2013; 34 1413 1432
18. Steigerwalt R., Nebbioso M., Appendino G., Belcaro G., Ciammaichella G., Cornelli U., Luzzi R., Togni S., Dugall M., Cesarone M. R., Ippolito E., Errichi B. M., Ledda A., Hosoi M., Corsi M. Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Med: 2012; 54 11 16
19. Chen M., Hu D. N., Pan Z., Lu C. W., Xue C. Y., Aass I. Curcumin protects against hyperosmoticity-induced IL-1beta elevation in human corneal epithelial cell via MAPK pathways. Exp Eye Res: 2010; 90 437 443
20. Alex A. F., Spitznas M., Tittel A. P., Kurts C., Eter N. Inhibitory effect of epigallocatechingallate (EGCG), resveratrol, and curcumin on proliferation of human retinal pigment epithelial cells in vitro. Curr Eye Res: 2010; 35 1021 1033
21. Mrudula T., Suryanarayana P., Srinivas P. N., Reddy G. B. Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. Biochem Biophys Res Commun: 2007; 361 528 532 (Pubitemid 47187290)
22. Gupta S. K., Kumar B., Nag T. C., Agrawal S. S., Agrawal R., Agrawal P., Saxena R., Srivastava S. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther: 2011; 27 123 130
23. Kowluru R. A., Kanwar M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr Metab (Lond): 2007; 16 4 8
24. Patumraj S., Wongeakin N., Sridulyakul P., Jariyapongskul A., Futrakul N., Bunnag S. Combined effects of curcumin and vitamin C to protect endothelial dysfunction in the iris tissue of STZ-induced diabetic rats. Clin Hemorheol Microcirc: 2006; 35 481 489 (Pubitemid 44812461)
25. Manikandan R., Thiagarajan R., Beulaja S., Sudhandiran G., Arumugam M. Curcumin prevents free radical-mediated cataractogenesis through modulations in lens calcium. Free Radic Biol Med: 2010; 48 483 492
26. Suryanarayana P., Krishnaswamy K., Reddy G. B. Effect of curcumin on galactose-induced cataractogenesis in rats. Mol Vis: 2003; 9 223 230 (Pubitemid 38097591)
27. Libby P., Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor- α and peroxisome proliferator-activated receptor- γ agonists. Am J Cardiol: 2007; 99 27B 40B
28. Arbiser J. L., Klauber N., Rohan R., van Leeuwen R., Huang M. T., Fisher C., Flynn E., Byers H. R. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med: 1998; 4 376 383 (Pubitemid 28387896)
29. Malchiodi-Albedi F., Matteucci A., Bernardo A. PPAR gamma, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches. PPAR Res: 2008; 2008 295784
30. Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., Dandona P. Nuclear factor- κ B suppressive and inhibitor- κ B stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab: 2001; 86 3250 3256 (Pubitemid 32674119)
31. Haffner S. M., Greenberg A. S., Weston W. M., Chen H., Williams K., Freed M. I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation: 2002; 106 679 684 (Pubitemid 34851926)
32. Marx N., Imhof A., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., Maerz W., Hombach V., Koenig W. Effect of rosiglitazone treatment on soluble CD40 L in patients with type 2 diabetes and coronary artery disease. Circulation: 2003; 107 1954 1957 (Pubitemid 36506065)
33. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab: 2004; 89 2728 2735
34. Wang G., Wei J., Guan Y., Jin N., Mao J., Wang X. Peroxisome proliferator-activated receptor- γ agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism: 2005; 54 590 597 (Pubitemid 40585648)
35. Agarwal R. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Renal Physiol: 2006; 290 F600 F605 (Pubitemid 43724959)
36. Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., Dandona P. Nuclear factor- κ B suppressive and inhibitor- κ B stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab: 2001; 86 3250 3256 (Pubitemid 32674119)
37. Haffner S. M., Greenberg A. S., Weston W. M., Chen H., Williams K., Freed M. I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation: 2002; 106 679 684 (Pubitemid 34851926)
38. Marx N., Imhof A., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., Maerz W., Hombach V., Koenig W. Effect of rosiglitazone treatment on soluble CD40 L in patients with type 2 diabetes and coronary artery disease. Circulation: 2003; 107 1954 1957 (Pubitemid 36506065)
39. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab: 2004; 89 2728 2735
40. Toda N., Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res: 2007; 26 205 238 (Pubitemid 46498800)
41. Murata T., He S., Hangai M., Ishibashi T., Xi X. P., Kim S., Hsueh W. A., Ryan S. J., Law R. E., Hinton D. R. Peroxisome proliferator-activated receptor- γ ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci: 2000; 41 2309 2317 (Pubitemid 30451008)
42. Bonne C. PPAR gamma: a novel pharmacological target against retinal and choroidal neovascularization. J Fr Ophtalmol: 2005; 28 326 330 (Pubitemid 40476970)
43. Sato M. Peroxisome proliferator activated receptor ligands and angiogenesis. Nihon Rinsho: 2005; 63 603 608
44. Sarayba M. A., Li L., Tungsiripat T. Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp Eye Res: 2005; 80 435 442 (Pubitemid 40249898)
45. Del Cano M. V, Gehlbach P. L. PPAR-alpha Ligands as potential therapeutic agents for wet age-related macular degeneration. PPAR Res: 2008; 2008 821592
46. Gralinski M. R., Rowse P. E., Breider M. A. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro. J Cardiovasc Pharmacol: 1998; 31 909 913 (Pubitemid 28265301)
47. Lee K. J., Kim H. A., Kim P. H., Lee H. S., Ma K. R., Park J. H., Kim D. J., Hahn J. H. Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR- γ Exp Mol Med: 2004; 36 534 544 (Pubitemid 40129175)
48. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J. C., Najib J., Duriez P., Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombininduced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res: 1999; 85 394 402 (Pubitemid 29409616)
49. Salvatore S., Vingolo E. M. Endothelin-1 role in human eye: a review. J Ophthalmol: 2010; 2010 354645
50. Combadière C., Feumi C., Raoul W., Keller N., Rodéro M., Pézard A., Lavalette S., Houssier M., Jonet L., Picard E., Debré P., Sirinyan M., Deterre P., Ferroukhi T., Cohen S. Y., Chauvaud D., Jeanny J. C., Chemtob S., Behar-Cohen F., Sennlaub F. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular de generation. J Clin Invest: 2007; 117 2920 2928 (Pubitemid 47529622)
51. Gregory M. S., Hackett C. G., Abernathy E. F., Lee K. S., Saff R. R., Hohlbaum A. M., Moody K. S., Hobson M. W., Jones A., Kolovou P., Karray S., Giani A., John S. W., Chen D. F., Marshak-Rothstein A., Ksander B. R. Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death. PLoS ONE: 2011; 6 e17659
52. Herzlich A. A., Tuo J., Chan C. C. Peroxisome proliferator-activated receptor and age-related macular degeneration. PPAR Res: 2008; 2008 389507
53. Passos E., Grinstead R. L., Khoobehi B. Effectiveness of curcumin, an angiogenesis inhibitor, in experimental choroidal neovascularization in rats. Invest Ophthalmol Vis Sci: 2002; 43 E-Abstract 1274
54. Diab A., Hussain R. Z., Lovett-Racke A. E., Chavis J. A., Drew P. D., Racke M. K. Ligands for the peroxisome proliferator-activated receptor- γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol: 2004; 148 116 126 (Pubitemid 38229564)
55. Jacob A., Wu R., Zhou M., Wang P. Mechanism of the anti-inflammatory effect of curcumin: PPAR- γ activation. PPAR Res: 2007; 2007 89369
56. Lal B., Kapoor A. K., Asthana O. P., Agrawal P. K., Prasad R., Kumar P., Srimal R. C. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res: 1999; 13 318 322 (Pubitemid 29308449)
57. Allegri P., Mastromarino A., Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin Ophthalmol: 2010; 4 1201 1206
58. Lal B., Kapoor A. K., Agrawal P. K., Asthana O. P., Srimal R. C. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res: 2000; 14 443 447
59. Graber-Maier A., Büter K. B., Aeschlimann J., Bittel C., Kreuter M., Drewe J., Gutmann H. Effects of Curcuma extracts and curcuminoids on expression of P-glycoprotein and cytochrome P450 3A4 in the intestinal cell culture model LS180. Planta Med: 2010; 76 1866 1870
60. Marczylo T. H., Verschoyle R. D., Cooke D. N., Morazzoni P., Steward W. P., Gescher A. J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol: 2007; 60 171 177 (Pubitemid 46742531)
61. Maiti K., Mukherjee K., Gantait A., Saha B. P., Mukherjee P. K. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm: 2007; 330 155 163 (Pubitemid 46097368)
62. Mazzolani F., Togni S. Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy: a 12-month follow-up study. Clin Ophthalmol: 2013; 7 939 945
63. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., Maitra A. Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy. J Nanobiotechnol: 2007; 5 3
64. Li L., Braiteh S. F., Kurzrock R. Liposome-encapsulated curcumin. in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer: 2005; 104 1322 1331 (Pubitemid 41282806)